|
The NYU Department of Psychiatry is interested
in continuing education of psychiatrists and
related professionals. This project is designed to provide psychiatrists
with a site to add to their knowledge of treating depression
using presentation slides and an opportunity to earn CME credit.
This program is sponsored by the Division of Continuing Education
in Psychiatry
Co-Director: Benjamin J. Sadock, M.D.
Slide design, Slide show and Program content
by Norman Sussman, M.D.,
The program is grateful to Robert Cancro, M.D., Chairman, NYU Department
of Psychiatry, for his continuous encouragement and support.
The program has 41 slides containing a text version and a references
list. You may participate in the program without charge by reviewing
the slide show. If you want to get CME credit click here.
Table of Contents
Issues Complicating the
Drug Treatment of Depression
Antidepressants
Strategies for Antidepressant
Nonresponse
Combination/Augmentation Therapy
Benefits of Antidepressant Combination/Augmentation Strategies
Antidepressant Augmentation Agents
Lithium
Lithium: Dosage and Adverse Effects
Thyroid Hormone
Thyroid Hormone: Dosage and Adverse Effects
5-HT1A Receptors
Drugs With Prominent 5-HT Receptor Activity
Neurotransmitter Receptor Hypothesis of Depression
Antidepressants: Mechanism of Action
Augmentation of SSRIs With 5-HT1A Agents: Mechanism of
Action
Pindolol
Pindolol and Serotonin
Structures
Prevention of the Inhibitory
Effect of Paroxetine on the Firing Activity
of 5-HT Neurons by
(-)Pindolol
Pindolol Reduction of
Paroxetine Latency Period
Effectiveness of Pindolol
With Selected Antidepressants in Major Depression
Pindolol: Dosage and
Adverse Effects
Pindolol: Summary
Buspirone: Receptor Pharmacology
Buspirone: Preclinical
Findings
Buspirone Clinical Characteristics
Improvement in 25-Item
HAM-D Scores: Buspirone vs. Placebo
Response to Treatment
With Buspirone or Placebo for Individual HAM-DSymptoms
Antidepressant Nonresponders
Completing Trial of Buspirone Potentiation
Winter-Relapsing Depressed
Patients Completing Trial of Buspirone Potentiation
Buspirone Augmentation
of Antidepressants: Case Histories
Buspirone Augmentation
of SSRIs in Refractory Depression: Open-Label Study
Buspirone Augmentation
of Serotonergic Antidepressants: Method
Results of Buspirone
Addition
Selective Activation
of Postsynaptic 5-HT1A Receptors and Rapid
Antidepressant Response
HAM-D Responses on Pindolol
and Trimipramine, Fluvoxamine, or Buspirone
Possible Combined Effects
of Buspirone and Pindolol on 5-HT1A Receptors
Buspirone Augmentation
as Treatment for SSRI Side Effects
Buspirone: Dosage and
Adverse Effects
Buspirone: Summary
Nutrients
Augmentation of Antidepressants:
Summary
REFERENCES
Questions and Answers
CME CREDIT
|
